Diabetes Insipidus (DI)

1. Topic Overview (Clinical Overview)

Summary

Diabetes Insipidus (DI) is a disorder of water homeostasis characterised by the excretion of abnormally large volumes of dilute urine (polyuria, typically > 3 L/day in adults) and compensatory excessive thirst (polydipsia). [1] The condition arises from either insufficient secretion of arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), from the posterior pituitary (Cranial or Central DI), or renal resistance to the action of AVP (Nephrogenic DI). [2]

In health, AVP is synthesised in the hypothalamus and released from the posterior pituitary in response to rising plasma osmolality or falling blood volume, promoting water reabsorption in the renal collecting ducts via aquaporin-2 (AQP2) water channels. [3] Disruption of this axis results in the kidney's inability to concentrate urine appropriately, leading to the characteristic biochemical profile: dilute urine (osmolality less than 300 mOsm/kg) in the presence of concentrated plasma (osmolality > 295 mOsm/kg). [1,4]

If patients cannot access water freely (e.g., unconscious patients, infants, cognitively impaired elderly, or post-operative states), severe life-threatening hypernatraemia (Na > 150 mmol/L) develops rapidly. [5] Diagnosis is confirmed by the water deprivation test, which demonstrates the kidney's failure to concentrate urine despite physiological stimuli, and distinguishes cranial from nephrogenic forms based on response to desmopressin (DDAVP). [4,6] Modern diagnostic approaches increasingly utilise copeptin, a stable surrogate marker of AVP, particularly following hypertonic saline infusion or arginine stimulation. [7,8]

Treatment of Cranial DI is desmopressin (DDAVP), a synthetic AVP analogue available in multiple formulations. [9,10] Nephrogenic DI management is more challenging and includes thiazide diuretics, amiloride (especially in lithium-induced cases), low-sodium diet, and treatment of underlying causes such as hypercalcaemia or discontinuation of offending medications. [2,11]

Key Facts

• Definition: Polyuria (> 40-50 mL/kg/day or > 3L/day in adults) + polydipsia due to AVP deficiency or renal resistance to AVP. [1]
• Types:
  • "Cranial (Central) DI: AVP deficiency from hypothalamic-pituitary damage."
  • "Nephrogenic DI: AVP resistance at the level of the kidney (V2 receptor or AQP2 dysfunction)."
  • "Gestational DI: Rare pregnancy-associated DI due to placental vasopressinase. [12]"
  • "Primary Polydipsia: Psychogenic or dipsogenic water intake causing secondary polyuria."
• Biochemistry: High or high-normal plasma osmolality (> 295 mOsm/kg), low urine osmolality (less than 300 mOsm/kg), often hypernatraemia (Na > 145 mmol/L).
• Diagnosis: Water deprivation test (gold standard) or copeptin-based testing. [4,7]
• Treatment (Cranial): Desmopressin (DDAVP) - intranasal, oral, sublingual, or parenteral.
• Treatment (Nephrogenic): Thiazides, amiloride, low-salt diet, treat underlying cause (e.g., stop lithium, correct hypercalcaemia). [2,11]

Clinical Pearls

"Inappropriate Dilution": The hallmark of DI is dilute urine when plasma is concentrated—a failure of the normal osmoregulatory response.

"Water Deprivation + Desmopressin Response": Cranial DI responds to desmopressin (urine concentrates > 50% increase in osmolality); nephrogenic DI does NOT (less than 50% increase or no response). [4]

"Post-Pituitary Surgery Vigilance": DI occurs in 10-30% of patients after transsphenoidal pituitary surgery. Watch for the "triphasic response": initial DI (days 1-5) → transient SIADH (days 5-10) → permanent DI (after day 10). [13,14]

"Lithium is the Leading Drug Cause of Nephrogenic DI": Chronic lithium therapy causes NDI in up to 40% of patients through downregulation of AQP2 and inhibition of adenylyl cyclase in collecting duct cells. [11,15]

"Copeptin is Revolutionising Diagnosis": Copeptin (C-terminal proAVP) is stable and measurable, unlike AVP. Stimulated copeptin levels less than 4.9 pmol/L after hypertonic saline or arginine infusion confirm cranial DI with high accuracy. [7,8]

"Posterior Pituitary Bright Spot": On T1-weighted MRI, the normal posterior pituitary appears as a hyperintense "bright spot" due to AVP-neurophysin granules. Its absence suggests cranial DI, though not diagnostic alone. [16]

"Thiazide Paradox": Thiazide diuretics paradoxically reduce urine output in nephrogenic DI by inducing mild volume depletion, which increases proximal tubular sodium and water reabsorption, reducing delivery to the collecting duct. [11]

Why This Matters Clinically

DI can cause life-threatening hypernatraemia if patients cannot communicate thirst or access water (post-operative, elderly, infants, neurologically impaired). Serum sodium > 160 mmol/L carries significant morbidity (seizures, coma) and mortality (up to 60% in severe cases). [5] Post-neurosurgical DI requires intensive monitoring and early recognition to prevent complications. Chronic untreated DI severely impairs quality of life through relentless nocturia, sleep disturbance, and social limitation. [17]

---

2. Epidemiology

Incidence and Prevalence

Diabetes insipidus is a rare disorder:

• Incidence: Estimated at 1 in 25,000 to 1 in 50,000 in the general population. [1,2]
• Cranial DI: Accounts for approximately 80-90% of all DI cases.
• Nephrogenic DI: Accounts for approximately 10-20% of DI cases.
• Congenital forms: Very rare, with X-linked nephrogenic DI affecting approximately 1 in 250,000 live births. [18]

Age and Sex Distribution

Causes of Diabetes Insipidus

Cranial (Central) Diabetes Insipidus

Nephrogenic Diabetes Insipidus

---

3. Pathophysiology

Normal AVP (Vasopressin) Physiology

AVP Synthesis and Secretion

AVP Renal Action

Thirst Mechanism

• Osmoreceptors in the OVLT also trigger thirst when plasma osmolality rises above 290-295 mOsm/kg.
• Thirst is a critical compensatory mechanism in DI. If thirst is intact and water is freely accessible, patients can maintain near-normal plasma osmolality despite massive polyuria.
• Loss of thirst (adipsia/hypodipsia) or inability to access water leads to rapid severe hypernatraemia. [1]

---

Pathophysiology of Cranial (Central) Diabetes Insipidus

Mechanisms

Post-Neurosurgical Triphasic Response

Following pituitary surgery or severe hypothalamic injury, some patients exhibit a triphasic pattern: [13,14]

Note: Not all patients follow this pattern. Many have only transient DI (resolves within days to weeks) or no DI if less than 80% of AVP neurons are damaged. [14]

---

Pathophysiology of Nephrogenic Diabetes Insipidus

Mechanisms

Lithium-Induced Nephrogenic DI

Lithium is the most common acquired cause of nephrogenic DI: [11,15]

• Prevalence: 20-40% of patients on chronic lithium therapy develop NDI.
• Mechanism:
  • Lithium enters principal cells via epithelial sodium channels (ENaC) on the apical membrane.
  • Lithium inhibits adenylyl cyclase, reducing cAMP production in response to AVP.
  • Lithium inhibits glycogen synthase kinase-3 (GSK-3), activating downstream pathways that downregulate AQP2 gene expression.
  • Lithium causes structural damage to collecting duct cells over time.
• Reversibility: Partial or complete reversal if lithium is stopped early (within months). After years of therapy, NDI may become irreversible due to structural tubular damage. [15]
• Treatment: Amiloride (blocks ENaC, reducing lithium entry into cells) is first-line for lithium-induced NDI if lithium cannot be stopped. [11]

---

4. Clinical Presentation

Cardinal Symptoms

Presentations by Patient Group

Physical Examination Findings

---

5. Investigations

Initial Biochemical Assessment

Key Diagnostic Criterion: Dilute urine (osmolality less than 300 mOsm/kg) in the presence of high plasma osmolality (> 295 mOsm/kg) or hypernatraemia. This represents a failure of normal osmoregulation. [1,4]

---

Water Deprivation Test (Traditional Gold Standard)

The water deprivation test assesses the kidney's ability to concentrate urine in response to dehydration and differentiates cranial from nephrogenic DI. [4,6]

Protocol (Simplified)

Interpretation

Limitations and Risks

• Dangerous in severe DI: Risk of severe dehydration, hypernatraemia, hypovolaemic shock. Requires close monitoring.
• Water intoxication risk: After desmopressin, patients must limit fluid intake to avoid hyponatraemia.
• Misdiagnosis of partial cranial DI vs primary polydipsia: Can be challenging; copeptin testing may help. [7]

---

Copeptin-Based Diagnostic Testing (Modern Approach)

Copeptin is a 39-amino acid glycopeptide derived from the C-terminal portion of the AVP precursor (proAVP). It is secreted in equimolar amounts with AVP but is stable in plasma (unlike AVP) and easily measurable. [7,8]

Copeptin Testing Protocols

Advantages over Water Deprivation Test: [7,8]

• Safer: Avoids prolonged dehydration and hypernatraemia risk.
• Faster: Completed in 2-3 hours vs. 8-18 hours.
• More accurate: Better discrimination between partial cranial DI and primary polydipsia.
• Patient-friendly: Less discomfort.

Copeptin testing is becoming the preferred diagnostic modality, particularly in specialist centres, though water deprivation test remains widely used. [7]

Future Directions: Basal copeptin alone (without stimulation) may be sufficient for diagnosis in some cases: copeptin less than 2.6 pmol/L strongly suggests cranial DI, while copeptin > 21.4 pmol/L suggests nephrogenic DI or primary polydipsia. Intermediate values require stimulation testing. [7,8]

---

Diagnostic Algorithm: Polyuria-Polydipsia Syndrome

Patient with Polyuria (> 3 L/day) + Polydipsia
          ↓
Exclude Osmotic Diuresis:
- Glucose (DM), Calcium (hypercalcaemia),
- Post-obstructive uropathy, ATN recovery
          ↓
Paired Plasma + Urine Osmolality
          ↓
   ┌────────────────┴────────────────┐
   ↓                                  ↓
Plasma Osm HIGH (> 295)          Plasma Osm LOW (less than 285)
Urine Osm LOW (less than 300)            Urine Osm LOW (less than 300)
   ↓                                  ↓
DIABETES INSIPIDUS              PRIMARY POLYDIPSIA
   ↓                            (Psychogenic/Dipsogenic)
Differentiate Cranial vs           ↓
Nephrogenic DI:               Water Deprivation Test:
   ↓                          Urine eventually concentrates
Option 1: COPEPTIN TEST       (> 600 mOsm/kg) after 12-18h
Hypertonic Saline or Arginine  (medullary gradient restored)
   ↓                                  ↓
Copeptin less than 4.9 pmol/L          Psychiatric evaluation
= CRANIAL DI                  (psychogenic)
   ↓                          OR
Copeptin > 21 pmol/L           MRI brain (dipsogenic:
= NEPHROGENIC DI              hypothalamic lesion)
   ↓
Option 2: WATER DEPRIVATION TEST
Deprive fluids 8-12h
   ↓
Urine remains dilute → Give DDAVP
   ↓
   ┌──────────┴──────────┐
   ↓                      ↓
Urine concentrates    Urine stays dilute
> 50% increase         less than 50% increase
   ↓                      ↓
CRANIAL DI          NEPHROGENIC DI
   ↓                      ↓
MRI Pituitary       Identify cause:
(tumour,            Lithium? Calcium?
infiltration,       Potassium? CKD?
idiopathic)         Genetic testing
                    (congenital)

---

Imaging

Note: Absence of the bright spot is suggestive but not diagnostic of cranial DI. It can be absent in ~20% of normal individuals and may persist in some patients with DI. [16]

---

Additional Investigations to Identify Cause

---

6. Differential Diagnosis: Polyuria-Polydipsia Syndrome

---

7. Management

Principles of Management

1. Ensure Adequate Fluid Access: The most critical intervention. Patients must have unrestricted access to water to prevent hypernatraemia. [1]
2. Identify and Treat Underlying Cause: Stop offending medications (lithium, demeclocycline), correct hypercalcaemia/hypokalaemia, treat pituitary tumours, etc.
3. Specific Hormone Replacement (Cranial DI): Desmopressin (DDAVP) replaces AVP.
4. Reduce Urine Output (Nephrogenic DI): Thiazides, amiloride, low-salt diet.
5. Monitor Sodium Closely: Avoid both hyper- and hyponatraemia (especially with DDAVP therapy).
6. Educate Patient: Recognize symptoms of hyper/hyponatraemia, medication adherence, medical alert identification. [17]

---

Management of Cranial (Central) Diabetes Insipidus

Desmopressin (DDAVP) Therapy

Desmopressin is a synthetic analogue of AVP with:

• Longer half-life (~8-12 hours vs. 5-20 minutes for AVP).
• Selective V2 receptor agonism (minimal V1 activity, thus minimal vasoconstriction/hypertension).
• Resistant to vasopressinase (unlike endogenous AVP; thus effective in gestational DI). [9,10]

Dosing Strategy

• Start Low, Titrate Slowly: Begin with lowest dose (e.g., 10 mcg intranasal or 100 mcg oral at bedtime) to control nocturia first.
• Assess Response: Reduce urine output, reduce nocturia, normalise serum Na.
• Titrate to Effect: Increase dose if polyuria persists. Typical maintenance: 10-20 mcg intranasal BD or 100-200 mcg oral BD. [9,10]
• Allow Breakthrough Polyuria: Patients should experience mild polyuria ("breakthrough") at least once every 24-48 hours to clear free water and prevent hyponatraemia. [9]

Monitoring

Risks and Side Effects

---

Management of Nephrogenic Diabetes Insipidus

Nephrogenic DI is more challenging to treat as desmopressin is ineffective. [2,11]

Step 1: Treat Underlying Cause

Step 2: Dietary Sodium Restriction

• Low-sodium diet (less than 2-3 g/day or less than 100 mmol/day): Reduces solute load delivered to collecting duct, reducing obligatory urine output.
• Can reduce urine output by 30-50%. [11]

Step 3: Thiazide Diuretics (Paradoxical Effect)

Mechanism: Thiazides induce mild volume depletion → increased proximal tubular reabsorption of sodium and water → reduced fluid delivery to distal tubule and collecting duct → reduced urine output (despite diuretic action in distal tubule). [11]

Monitoring: Serum potassium (risk of hypokalaemia), serum sodium, renal function.

Combination with Amiloride: Often used together, especially in lithium-induced NDI (see below).

Step 4: Amiloride (Especially for Lithium-Induced NDI)

Mechanism:

• Blocks epithelial sodium channels (ENaC) on the apical membrane of collecting duct cells.
• Reduces lithium entry into principal cells (lithium enters via ENaC).
• Protects cells from intracellular lithium toxicity and reduces AQP2 downregulation. [11]

Monitoring: Serum potassium (amiloride is potassium-sparing; risk of hyperkalaemia if combined with ACE inhibitors or in CKD).

Step 5: NSAIDs (Indomethacin)

Mechanism:

• Inhibit renal prostaglandin synthesis.
• Prostaglandins inhibit ADH action; NSAIDs remove this inhibition, enhancing residual ADH effect.
• Also reduce GFR slightly, reducing urine output.

Risks: GI side effects, renal impairment, cardiovascular risk. Reserved for refractory cases.

Step 6: High-Dose Desmopressin (Occasional Partial Response)

In some cases of partial nephrogenic DI (e.g., mild AVPR2 mutations), very high doses of desmopressin (e.g., 40-60 mcg intranasal or 400-800 mcg oral) may produce partial response by overcoming receptor resistance. [2]

• Not effective in complete NDI.
• Trial may be worthwhile in selected patients.

Congenital Nephrogenic DI (Infants/Children)

• Ensure adequate hydration: Frequent feeds (every 2 hours), free access to water.
• Thiazide + amiloride: Start early to reduce urine output and prevent dehydration/hypernatraemia.
• Low-sodium diet: Essential (age-appropriate).
• Monitor growth and development closely: Chronic hypernatraemia impairs neurodevelopment. [18]
• Avoid NSAIDs in infants: Risk of renal impairment, necrotising enterocolitis.

---

Acute Management: Hypernatraemia and Dehydration

Chronic Hypernatraemia (> 48 hours): Brain cells adapt by generating intracellular organic osmolytes (taurine, myoinositol) to protect against cell shrinkage. Rapid correction causes relative hypoosmolality → water influx → cerebral oedema → seizures, coma, death. [5]

Hypernatraemia Correction Rate: Maximum 10-12 mmol/L per 24 hours; ideally 6-8 mmol/L per 24 hours. Slower if chronic.

---

Management Algorithm for Hypernatraemia in DI

Hypernatraemia (Na > 150 mmol/L) in DI Patient
          ↓
 Assess Volume Status
          ↓
   ┌──────┴──────┐
   ↓              ↓
Hypovolaemic    Euvolaemic
(Shock, ↓BP)   (Stable)
   ↓              ↓
0.9% NaCl      Calculate Free
500 mL bolus   Water Deficit
Repeat PRN        ↓
   ↓           Replace with
Stabilise      5% Dextrose or
Haemodynamics  0.45% NaCl IV
   ↓              ↓
   └──────┬───────┘
          ↓
    If Cranial DI:
Give Desmopressin 2-4 mcg IM/SC
    (once volume replete)
          ↓
    Correct Na slowly:
   less than 10-12 mmol/L per 24 hrs
          ↓
  Monitor Na q4-6h
  Monitor Urine Output
  Monitor Neuro Status
          ↓
   Transition to Oral
   Fluids + Long-term
   DDAVP (Cranial DI)
   or Thiazides (Nephrogenic DI)

---

Post-Neurosurgical DI: Specific Management

Key Point: In post-operative setting, give desmopressin "as needed" rather than scheduled doses in the first 10 days to avoid masking the SIADH phase. [13,14]

---

8. Complications

---

9. Prognosis and Outcomes

Mortality: DI itself is not directly life-threatening if thirst is intact and water is accessible. Mortality arises from:

• Severe hypernatraemia (especially if acute or Na > 160 mmol/L): 40-60% mortality. [5]
• Complications of underlying cause (e.g., malignant brain tumour, metastatic cancer).

---

10. Evidence and Guidelines

Key Evidence

Guidelines

---

10. Special Situations and Clinical Scenarios

Diabetes Insipidus in Pregnancy

Diabetes Insipidus in Critical Care

Paediatric Considerations

Diabetes Insipidus and Other Pituitary Hormone Deficiencies

Adipsic Diabetes Insipidus

Drug-Induced Diabetes Insipidus

---

11. Examination Focus (MRCP/FRACP)

PACES Station 5: Brief Clinical Consultation

Scenario: "This 35-year-old man presents with excessive thirst and urinating 8-10 times per night. Please take a brief history and suggest initial investigations."

Key History:

• Polyuria: Quantify (litres/day? Nocturia frequency?). Duration of symptoms. Pale, dilute urine?
• Polydipsia: Intensity of thirst. Fluid intake (litres/day?). Preference for cold water?
• Dehydration symptoms: Dizziness, weight loss, dry mouth.
• Recent neurosurgery or head trauma: Post-pituitary surgery is a classic cause.
• Medications: Lithium (key!), demeclocycline.
• Systemic symptoms: Headaches, visual changes (pituitary tumour?), weight loss (malignancy?), bone pain (LCH, metastases?).
• Family history: Congenital DI (rare).

Key Investigations to Suggest:

• Paired plasma and urine osmolality (first-line).
• Serum sodium, glucose (exclude DM), calcium, potassium.
• 24-hour urine volume (confirm polyuria).
• Water deprivation test or copeptin testing (diagnostic).
• MRI pituitary (if cranial DI suspected).

Key Differentials:

• Diabetes mellitus (check glucose).
• Primary polydipsia (low plasma osmolality).
• Nephrogenic DI (lithium, hypercalcaemia).

Viva Questions

Q1: What is the difference between cranial and nephrogenic diabetes insipidus?

Model Answer: "Cranial DI is due to deficiency of AVP secretion from the posterior pituitary, commonly caused by idiopathic autoimmune damage, pituitary surgery, tumours like craniopharyngioma, or infiltrative diseases like sarcoidosis. Nephrogenic DI is due to renal resistance to AVP at the level of the V2 receptor or aquaporin-2 water channels. The most common acquired cause is lithium therapy, which downregulates AQP2 and impairs AVP signalling. Hypercalcaemia and hypokalaemia also cause nephrogenic DI by interfering with the medullary concentrating gradient."

Q2: Describe the water deprivation test.

Model Answer: "The water deprivation test is the traditional gold standard for diagnosing DI. The patient is deprived of fluids for 8-12 hours while monitoring weight, urine osmolality, and plasma osmolality. The test is stopped when plasma osmolality exceeds 300 mOsm/kg, weight loss exceeds 3-5%, or urine osmolality plateaus. At this point, desmopressin (2-4 mcg IM/SC or 10 mcg intranasal) is administered and urine osmolality is measured 1-4 hours later. In cranial DI, urine osmolality increases by > 50% after desmopressin. In nephrogenic DI, there is little or no response (less than 50% increase). In primary polydipsia, urine concentrates to > 600 mOsm/kg during dehydration without needing desmopressin, though initial concentrating ability may be impaired due to medullary washout from chronic polydipsia." [4,6]

Q3: What is the triphasic response after pituitary surgery?

Model Answer: "The triphasic response is seen in some patients following pituitary surgery or severe hypothalamic injury. Phase 1 (days 1-5) is acute DI due to axonal shock and impaired AVP release, causing polyuria and hypernatraemia, requiring desmopressin or IV fluids. Phase 2 (days 5-10) is transient SIADH caused by uncontrolled AVP release from dying neurosecretory neurons, leading to oliguria and hyponatraemia; desmopressin must be stopped and fluid restriction initiated. Phase 3 (after day 10) is permanent DI if > 80-90% of AVP neurons are destroyed, requiring lifelong desmopressin therapy. Not all patients exhibit the full triphasic pattern; many have only transient DI that resolves." [13,14]

Q4: How does lithium cause nephrogenic diabetes insipidus?

Model Answer: "Lithium causes nephrogenic DI by multiple mechanisms. First, lithium enters principal cells of the collecting duct via epithelial sodium channels (ENaC) on the apical membrane. Inside the cell, lithium inhibits adenylyl cyclase, reducing cAMP production in response to AVP, thus impairing V2 receptor signalling. Lithium also inhibits glycogen synthase kinase-3 (GSK-3), which leads to downregulation of aquaporin-2 gene expression, reducing the number of water channels available. Chronic lithium therapy causes structural tubular damage. Lithium-induced NDI affects 20-40% of patients on long-term therapy. It is partially reversible if lithium is stopped early, but often becomes irreversible after years of therapy. Amiloride is used to block ENaC and reduce lithium entry into cells, protecting against NDI progression." [11,15]

Q5: Why do thiazide diuretics reduce urine output in nephrogenic diabetes insipidus?

Model Answer: "This is known as the thiazide paradox. Thiazides act on the distal convoluted tubule to inhibit sodium-chloride cotransport, causing sodium and water loss. This induces mild volume depletion, which stimulates the renin-angiotensin-aldosterone system and increases proximal tubular reabsorption of sodium and water as a compensatory mechanism. As a result, less fluid is delivered to the distal tubule and collecting duct, reducing the volume of urine produced despite the kidney's inability to concentrate urine. Thiazides can reduce urine output by 30-50% in nephrogenic DI and are often combined with a low-sodium diet to further reduce solute load and amiloride (particularly in lithium-induced NDI) to block lithium entry into cells." [11]

Q6: What is copeptin and how is it used in diagnosing diabetes insipidus?

Model Answer: "Copeptin is a 39-amino acid glycopeptide derived from the C-terminal portion of the AVP precursor (proAVP). It is secreted in equimolar amounts with AVP but, unlike AVP, is stable in plasma and easily measurable. Copeptin serves as a surrogate marker for AVP. In copeptin-based diagnostic testing, hypertonic saline (3% NaCl) or arginine is infused to stimulate AVP/copeptin release. A stimulated copeptin level less than 4.9 pmol/L (hypertonic saline test) or less than 3.8 pmol/L (arginine test) confirms cranial DI with 95% sensitivity and 96% specificity. Copeptin > 21 pmol/L at baseline suggests nephrogenic DI (elevated AVP due to renal resistance). Copeptin testing is safer, faster, and more accurate than the water deprivation test and is increasingly preferred in specialist centres." [7,8]

Q7: What is the most serious complication of diabetes insipidus and how is it managed?

Model Answer: "The most serious complication is severe hypernatraemia (serum Na > 160 mmol/L), which can cause confusion, seizures, coma, and intracerebral haemorrhage due to brain cell shrinkage and vascular rupture. Mortality is 40-60% when Na exceeds 160 mmol/L. Hypernatraemia develops when patients cannot access water (unconscious, post-operative, infants, cognitively impaired elderly). Management involves slow correction to avoid cerebral oedema. First, restore circulating volume with 0.9% NaCl bolus if hypovolaemic. Then replace the free water deficit using 5% dextrose or 0.45% NaCl IV, aiming to reduce serum sodium by less than 10-12 mmol/L per 24 hours (ideally 6-8 mmol/L per 24 hours). In cranial DI, give desmopressin 2-4 mcg IM/SC once volume replete to reduce ongoing urinary losses. Monitor serum sodium every 4-6 hours and adjust IV fluids accordingly. Too-rapid correction causes relative plasma hypoosmolality, leading to cerebral oedema, seizures, and death." [5]

---

Clinical Case Scenarios for MRCP/FRACP

Case 1: Post-Neurosurgical DI with Triphasic Response

Day 1 Post-Op: 42-year-old woman, day 1 after transsphenoidal resection of non-functioning pituitary macroadenoma. Urine output 350 mL/hr for 3 consecutive hours. Urine pale and dilute. Thirsty.

Investigations: Na 146 mmol/L, Plasma osm 308 mOsm/kg, Urine osm 180 mOsm/kg.

Q1: Diagnosis? A1: Acute cranial DI (post-neurosurgical, Phase 1 of potential triphasic response).

Q2: Immediate management? A2:

• Confirm DI with paired plasma/urine osm (already done).
• Give desmopressin 2 mcg IM/SC as single dose (not regular dosing yet - watch for triphasic response).
• Reduce IV fluid rate to avoid hyponatraemia once DDAVP takes effect.
• Monitor urine output hourly, serum Na q6-12h.

Day 6 Post-Op: Polyuria has resolved. Now urine output only 20 mL/hr for 6 hours. Na 130 mmol/L (was 143 yesterday). Patient headache, mild nausea.

Q3: What has happened? A3: Entered Phase 2: SIADH (triphasic response). Uncontrolled AVP release from dying posterior pituitary neurons → oliguria + hyponatraemia.

Q4: Management? A4:

• Stop desmopressin immediately.
• Fluid restrict to 500-1000 mL/day.
• Monitor Na q6-12h (may need hypertonic saline if Na drops less than 125 mmol/L or symptoms severe).
• Educate team: Do NOT restart DDAVP during this phase.

Day 12 Post-Op: Na normalised to 138 mmol/L on fluid restriction. Now polyuria recurs: urine output 4 L/day, thirsty.

Q5: What now? A5: Entered Phase 3: Permanent DI. Posterior pituitary neurons permanently destroyed.

• Restart desmopressin (now as regular therapy).
• Start oral desmopressin 100 mcg BD (preferred for long-term use).
• Titrate dose to control polyuria/nocturia.
• Endocrine outpatient follow-up arranged.
• Check for anterior pituitary deficiency (9 AM cortisol, TFTs, LH/FSH, IGF-1).

Key Learning Points:

• Triphasic response occurs in ~10-20% of pituitary surgery patients.
• Do NOT give scheduled DDAVP doses in first 10 days - use "as needed" approach.
• Watch for SIADH phase (can be life-threatening if unrecognised).
• Permanent DI likely if polyuria recurs after day 10-14.

---

Case 2: Lithium-Induced Nephrogenic DI

Presentation: 55-year-old man with bipolar disorder, on lithium 800 mg BD for 8 years. Presents with 6-month history of polyuria (8-10 L/day), polydipsia, nocturia 7-8 times/night. "Can't sleep anymore, affecting my work."

Investigations:

• Na 148 mmol/L, K 3.8 mmol/L, Creatinine 105 μmol/L (eGFR 65 mL/min).
• Plasma osm 310 mOsm/kg, Urine osm 195 mOsm/kg.
• Lithium level 0.9 mmol/L (therapeutic range 0.6-1.0).
• 24-hr urine volume: 9 litres.

Q1: Diagnosis? A1: Nephrogenic diabetes insipidus secondary to chronic lithium therapy.

Q2: Why does lithium cause this? A2: Lithium enters collecting duct principal cells via ENaC channels. Inside cells, lithium inhibits adenylyl cyclase (reducing cAMP response to AVP) and inhibits GSK-3 (downregulating aquaporin-2 gene expression). Result: kidney resistance to AVP. Affects 20-40% of chronic lithium users. [11,15]

Q3: Water deprivation test - expected result? A3: Urine would remain dilute (less than 300 mOsm/kg) despite dehydration AND after desmopressin administration (nephrogenic DI = no response to DDAVP).

Q4: Management options - discuss with patient and psychiatrist. A4:

1. Discontinue lithium (if psychiatrically safe - consult psychiatrist for alternative mood stabiliser, e.g., valproate, olanzapine). Partial recovery possible if stopped early.
2. If lithium must continue:
   • Add amiloride 5 mg BD (blocks lithium entry into collecting duct cells via ENaC). Can reduce urine output by 30-40%. [11]
   • Thiazide diuretic (hydrochlorothiazide 25 mg OD) - paradoxically reduces urine output by 30-50%. Can combine with amiloride (potassium-sparing).
   • Low-sodium diet (less than 2-3 g/day) - reduces solute load.
   • Monitor Na, K weekly initially (thiazides cause hypokalaemia; amiloride is K-sparing).
3. If lithium stopped: Partial resolution over weeks-months. May not fully reverse if 8 years of exposure (structural tubular damage).

Q5: What about desmopressin? A5: Generally ineffective in nephrogenic DI (kidney resistant to AVP). Occasionally, very high doses of DDAVP (e.g., 60 mcg intranasal or 400-800 mcg oral) produce partial response in mild cases, but not recommended as first-line.

Outcome: Psychiatrist switches to valproate. Amiloride 5 mg BD + hydrochlorothiazide 25 mg OD + low-salt diet initiated. At 3-month follow-up: urine output reduced to 5 L/day, nocturia 3-4 times/night (improved but not fully resolved). Na 144 mmol/L, K 4.0 mmol/L. Patient reports improved quality of life and sleep.

---

Case 3: Adipsic DI - The Dangerous Combination

Presentation: 28-year-old woman, 3 months post-resection of craniopharyngioma. Presents to clinic with lethargy, confusion. On desmopressin 10 mcg intranasal BD for known post-operative DI.

Observations: GCS 14 (E4 V4 M6), HR 95, BP 110/70, temp 37.2°C.

Investigations:

• Na 162 mmol/L (was 140 at last clinic visit 4 weeks ago).
• Plasma osm 338 mOsm/kg.
• Glucose 5.8 mmol/L.
• Patient reports no thirst. "I forget to drink water. I'm just not thirsty even though I know I should drink."

Q1: What additional problem has developed? A1: Adipsic diabetes insipidus. Craniopharyngioma (or its resection) has damaged hypothalamic osmoreceptors (OVLT, subfornical organ), causing loss of thirst (adipsia). Patient has DI but no compensatory thirst → severe chronic hypernatraemia. [1]

Q2: Why is this so dangerous? A2: Normal DI patients maintain near-normal Na via compensatory thirst (drink to match urinary losses). In adipsic DI, patients have no urge to drink despite high Na → chronic severe hypernatraemia (Na often 150-165 mmol/L). High risk of seizures, coma, intracerebral haemorrhage. Cannot rely on thirst to regulate water intake.

Q3: Immediate management of Na 162 mmol/L? A3:

• Admit to hospital.
• IV 5% dextrose to replace free water deficit. Deficit = 0.6 × 60 kg × [(162/140) - 1] = 5.7 L.
• Correct slowly: less than 10 mmol/L per 24 hours (aim for Na 152 by tomorrow). Give ~2-3 L dextrose over 24h, monitor Na q6h.
• Continue desmopressin (controls DI, reduces ongoing losses).
• Oral fluids if able (encourage, but she has no thirst drive).

Q4: Long-term management strategy? A4:

1. Prescribe fixed daily water intake: E.g., "Drink 3 litres per day in divided doses" (500 mL q4h while awake). Use smartphone app reminders or alarm clock. Not "drink when thirsty" (she has no thirst!).
2. Desmopressin: Continue, but titrate carefully (risk of hyponatraemia if water intake excessive and urine output too suppressed).
3. Frequent Na monitoring: Weekly initially, then every 2-4 weeks once stable. Home Na monitoring (point-of-care testing) may be considered.
4. Patient/carer education: Explain loss of thirst. Water intake is a "prescription" like medication. Recognise symptoms of hyper/hyponatraemia.
5. Medical alert bracelet: "Adipsic diabetes insipidus. Do not restrict fluids."
6. Specialist endocrine follow-up: Lifelong. Very challenging condition to manage.

Key Learning Point: Adipsic DI is one of the most difficult endocrine emergencies to manage long-term. Requires meticulous patient education and close monitoring. [1]

---

Case 4: Gestational DI

Presentation: 32-year-old woman, 34 weeks pregnant (G2P1). Sudden onset of severe polyuria (12 L/day) and polydipsia over 1 week. No previous medical history. First pregnancy was uncomplicated.

Investigations:

• Na 149 mmol/L, K 4.0 mmol/L, Creatinine 58 μmol/L (pregnancy-related low Cr).
• Plasma osm 312 mOsm/kg, Urine osm 175 mOsm/kg.
• Glucose normal (exclude gestational diabetes).
• Liver enzymes mildly elevated (ALT 65, AST 58).

Q1: Differential diagnosis? A1:

1. Gestational diabetes insipidus (most likely - sudden onset in 3rd trimester).
2. Pre-existing cranial DI unmasked by pregnancy.
3. Pre-eclampsia with hepatic dysfunction (though BP normal, no proteinuria).

Q2: What causes gestational DI? A2: Placenta produces vasopressinase enzyme that degrades endogenous AVP (arginine vasopressin). In most women, increased AVP production compensates. In rare cases (~2-4 per 100,000 pregnancies), vasopressinase activity overwhelms AVP production → DI. Desmopressin is resistant to vasopressinase degradation, so DDAVP is effective. [12]

Q3: How to confirm diagnosis? A3: Therapeutic trial of desmopressin. Give desmopressin 10 mcg intranasal or 100 mcg oral. If gestational DI: dramatic reduction in polyuria within hours (confirms AVP deficiency that responds to DDAVP, not nephrogenic DI). Copeptin would be low (if available).

Q4: Management? A4:

• Desmopressin: Start 10 mcg intranasal OD or 100 mcg oral BD. Safe in pregnancy. Titrate to control symptoms.
• Monitor Na weekly (risk of hyponatraemia if overdosed).
• Monitor liver function (rare association with hepatic dysfunction/acute fatty liver of pregnancy - resolve DI if liver dysfunction worsens).
• Obstetric input: Monitor fetal well-being (CTG, growth scans).
• Plan delivery: Condition does not necessitate early delivery unless obstetric indications. Can aim for term.

Q5: What happens post-delivery? A5: Gestational DI resolves within days postpartum (placenta delivered → vasopressinase production stops → endogenous AVP sufficient). Stop desmopressin 24-48h post-delivery. Check Na at 1 week postpartum to confirm resolution. If DI persists, suggests underlying cranial DI (not purely gestational) - needs MRI pituitary and endocrine follow-up.

Outcome: Patient started on desmopressin 100 mcg oral BD. Polyuria resolved within 24 hours. Delivered healthy baby at 39 weeks. Desmopressin stopped day 2 postpartum. Na 138 mmol/L at 1-week postnatal check. No polyuria. Diagnosis: Gestational DI (resolved).

---

Case 5: Distinguishing Primary Polydipsia from DI

Presentation: 35-year-old man with schizophrenia, chronic polyuria and polydipsia (10-12 L/day) for 2 years. Psychiatric history of compulsive water drinking. No medications affecting kidneys.

Investigations:

• Na 132 mmol/L (low-normal).
• Plasma osm 280 mOsm/kg (low-normal).
• Urine osm 150 mOsm/kg (dilute).
• 24-hr urine: 11 litres.

Q1: Why is this NOT diabetes insipidus? A1: In DI, plasma osmolality is high or high-normal (> 295 mOsm/kg) due to inability to retain water. This patient has low plasma osmolality (280 mOsm/kg), indicating water overload. The dilute urine is appropriate (kidneys correctly excreting excess water). This is primary polydipsia (compulsive/psychogenic water drinking). [1,4]

Q2: Water deprivation test - expected result? A2:

• Initially: Urine remains dilute for several hours (medullary concentrating gradient has been "washed out" by chronic high water intake).
• After 12-18 hours: Medullary gradient is restored → urine concentrates to > 600 mOsm/kg (normal response).
• No response to desmopressin needed (endogenous AVP function is normal).

This distinguishes primary polydipsia from DI (in DI, urine would NOT concentrate during dehydration). [4]

Q3: Management? A3:

• Psychiatric management: Treat underlying psychosis (antipsychotics). Behavioural therapy to reduce compulsive water drinking.
• Fluid restriction (difficult to enforce in psychogenic polydipsia).
• No desmopressin (would worsen hyponatraemia).
• Monitor Na (risk of severe hyponatraemia if water drinking continues unchecked - "water intoxication" causing seizures, coma).

Key Differentiating Features:

---

Data Interpretation (Investigations Station)

Scenario: "A 28-year-old woman presents with polyuria. Biochemistry shows: Na 148 mmol/L, K 4.2 mmol/L, Glucose 5.5 mmol/L, Plasma osmolality 310 mOsm/kg, Urine osmolality 180 mOsm/kg. Interpret these results."

Model Answer: "The key finding is high plasma osmolality (310 mOsm/kg) with inappropriately low urine osmolality (180 mOsm/kg). Normally, when plasma osmolality exceeds 295 mOsm/kg, AVP should be released and urine should concentrate to > 600 mOsm/kg. The failure to concentrate urine despite concentrated plasma is diagnostic of diabetes insipidus. The hypernatraemia (Na 148 mmol/L) reflects free water loss exceeding intake. Glucose is normal, excluding diabetes mellitus. To differentiate cranial from nephrogenic DI, I would perform a water deprivation test with desmopressin or, preferably, copeptin testing. If cranial DI, urine would concentrate after desmopressin; if nephrogenic, it would not. I would also take a history regarding recent pituitary surgery, lithium use, and check serum calcium and potassium to exclude secondary causes of nephrogenic DI. An MRI pituitary would be indicated to look for structural lesions if cranial DI is confirmed."

---

Common Exam Traps

---

12. Patient/Layperson Explanation

What is Diabetes Insipidus?

Diabetes Insipidus (DI) is a condition where you pass very large amounts of watery urine (often 5-20 litres per day) and feel extremely thirsty all the time. It is not the same as diabetes mellitus (the common "sugar diabetes"). The name "diabetes" comes from the Greek word for "siphon" (referring to frequent urination), and "insipidus" means "tasteless" (because the urine is dilute and does not contain sugar, unlike diabetes mellitus).

What causes it?

Your body normally makes a hormone called vasopressin (also called ADH or antidiuretic hormone) in your brain. This hormone tells your kidneys to hold on to water and make concentrated urine. In DI, one of two things goes wrong:

1. Cranial (Central) DI: Your brain doesn't make enough vasopressin. This can happen after brain surgery, because of a tumour, or for unknown reasons (called "idiopathic").
2. Nephrogenic DI: Your brain makes enough vasopressin, but your kidneys don't respond to it. This is often caused by medications (especially lithium, used for bipolar disorder) or problems like high calcium or low potassium in your blood.

What are the symptoms?

• Passing large amounts of pale, watery urine (you may need to urinate every 1-2 hours, even at night).
• Intense thirst (you feel like you need to drink water constantly).
• Waking up many times at night to urinate (nocturia), which disrupts your sleep.
• Tiredness and fatigue (from lack of sleep and dehydration).

If you cannot drink enough water to replace what you are losing (for example, if you are unconscious or very unwell), your blood can become too concentrated (high sodium), which can cause confusion, seizures, or even coma. This is a medical emergency.

How is it diagnosed?

Your doctor will do blood and urine tests to measure the concentration of your blood and urine. In DI, your blood is too concentrated but your urine is too dilute (the opposite of what should happen).

You may need a water deprivation test, where you stop drinking water for several hours while doctors monitor your blood and urine. After this, you are given a medication called desmopressin to see if your kidneys respond. This test helps determine whether you have cranial or nephrogenic DI.

A newer test measures a marker in your blood called copeptin, which is safer and faster than the water deprivation test.

How is it treated?

For Cranial DI:

• You take a medication called desmopressin (DDAVP), which replaces the missing vasopressin hormone. It comes as a nasal spray, tablet, or injection.
• DDAVP reduces your urine output and thirst.
• You need to take it regularly (usually once or twice a day).
• Important: If you take too much DDAVP and drink too much water, your blood sodium can become too low (causing headaches, nausea, confusion). Your doctor will teach you to drink only when you feel thirsty, not out of habit.

For Nephrogenic DI:

• DDAVP doesn't work because your kidneys are resistant to it.
• Treatment includes:
  • Water pills (thiazides) (which, paradoxically, reduce urine output in this condition).
  • Amiloride (especially if your DI is caused by lithium).
  • Low-salt diet (reduces the workload on your kidneys).
  • Stopping or changing medications that are causing the problem (e.g., lithium).

Key Counselling Points

1. Always drink when you feel thirsty. If you have cranial DI and are taking DDAVP, you may not feel as thirsty, but do not force yourself to drink if you are not thirsty (this can cause your sodium to drop too low).
2. Take your DDAVP as prescribed. Do not take extra doses without consulting your doctor.
3. Wear a medical alert bracelet or carry a card saying you have diabetes insipidus. This is important if you become unconscious or need emergency treatment.
4. Tell all your doctors about your condition, especially before surgery or if you become unwell with vomiting or diarrhoea (you may need extra fluids or changes to your DDAVP dose).
5. Attend regular blood tests to monitor your sodium levels.

Will it go away?

• Cranial DI caused by surgery or trauma may be temporary (lasts a few weeks) or permanent (lifelong). If it is permanent, you will need to take DDAVP for life, but you can live a normal, healthy life.
• Nephrogenic DI caused by medications may improve if the medication is stopped early. Congenital (inherited) forms are lifelong.

What happens if it's not treated?

Without treatment, DI can cause severe dehydration, dangerously high sodium levels in your blood, and, in extreme cases, seizures or coma. However, if you have access to water and can drink freely, you can usually prevent these problems by responding to your thirst.

---

13. Related Topics

• Syndrome of Inappropriate ADH (SIADH): The opposite of DI—excessive AVP secretion causing hyponatraemia and concentrated urine.
• Hypernatraemia: Elevated serum sodium; DI is a common cause.
• Hyponatraemia: Low serum sodium; can be caused by DDAVP overdose in DI.
• Pituitary Adenoma: Can cause cranial DI via stalk compression or post-surgical complication.
• Hypopituitarism: Often coexists with cranial DI in patients with pituitary/hypothalamic damage.
• Craniopharyngioma: Suprasellar tumour; common cause of DI in children and young adults.
• Langerhans Cell Histiocytosis: Infiltrative disease causing cranial DI, especially in children.
• Lithium Toxicity: Major cause of nephrogenic DI.
• Acute Kidney Injury (AKI) / Chronic Kidney Disease (CKD): Can cause polyuria and concentrating defects.
• Primary Polydipsia: Psychogenic or dipsogenic excessive water drinking; key differential for polyuria-polydipsia syndrome.

---

14. Quality Markers: Audit Standards

---

15. Historical Context

• Etymology: The term "Diabetes Insipidus" was introduced in 1794 by Johann Peter Frank, distinguishing it from diabetes mellitus. "Diabetes" derives from Greek "diabētēs" (siphon, referring to polyuria). "Insipidus" is Latin for "tasteless", reflecting that the urine in DI lacks the sweet taste of glucose found in diabetes mellitus.
• Vasopressin Discovery: The antidiuretic hormone was isolated from the pituitary gland in the 1920s-1930s. Vincent du Vigneaud synthesised vasopressin in 1953 and determined its amino acid sequence, for which he won the Nobel Prize in Chemistry in 1955.
• Desmopressin Development: Desmopressin (DDAVP), a synthetic analogue of vasopressin with prolonged action and selective V2 receptor activity, was developed in the 1970s by Zaoral and colleagues. It revolutionised the treatment of cranial DI by providing a safe, effective, long-acting replacement.
• Aquaporin Discovery: Peter Agre discovered aquaporin-1 in 1988 and subsequently aquaporin-2 (the AVP-regulated water channel in the collecting duct). He was awarded the Nobel Prize in Chemistry in 2003 for this groundbreaking work, which elucidated the molecular basis of water reabsorption and nephrogenic DI. [19]
• Copeptin Era: The measurement of copeptin as a stable surrogate for AVP was introduced in the 2000s, with diagnostic protocols developed and validated in the 2010s-2020s, transforming DI diagnosis by replacing the cumbersome and risky water deprivation test. [7,8]

---

16. References

1. Christ-Crain M, Gurnell M. Diabetes insipidus. Nat Rev Dis Primers. 2019;5(1):54. PMID: 31395885 DOI: 10.1038/s41572-019-0103-2

2. Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol. 2015;11(10):576-88. PMID: 26077742 DOI: 10.1038/nrneph.2015.89

3. Angelousi A, Larger E, Kamenicky P. New developments and concepts in the diagnosis and management of diabetes insipidus. J Neuroendocrinol. 2023;35(3):e13233. PMID: 36683321 DOI: 10.1111/jne.13233

4. Refardt J, Winzeler B, Christ-Crain M. Diabetes Insipidus: An Update. Endocrinol Metab Clin North Am. 2020;49(3):517-531. PMID: 32741486 DOI: 10.1016/j.ecl.2020.05.012

5. Vaz de Castro PAS, Bitzan M, Banerjee S, Bockenhauer D. Nephrogenic diabetes insipidus: a comprehensive overview. J Pediatr Endocrinol Metab. 2022;35(4):421-434. PMID: 35146976 DOI: 10.1515/jpem-2021-0566

6. Di Iorgi N, Napoli F, Allegri AE, et al. Diabetes insipidus--diagnosis and management. Horm Res Paediatr. 2012;77(2):69-84. PMID: 22433947 DOI: 10.1159/000336333

7. Tomkins M, Lawson EA, Hollinshead M, et al. Diagnosis and Management of Central Diabetes Insipidus in Adults. J Clin Endocrinol Metab. 2022;107(10):2701-2715. PMID: 35771962 DOI: 10.1210/clinem/dgac381

8. Christ-Crain M, Winzeler B, Refardt J. Diagnosis and management of diabetes insipidus for the internist: an update. J Intern Med. 2021;290(1):73-87. PMID: 33713498 DOI: 10.1111/joim.13261

9. Garrahy A, Moran C, Thompson CJ. Management of central diabetes insipidus. Best Pract Res Clin Endocrinol Metab. 2020;34(5):101385. PMID: 32169331 DOI: 10.1016/j.beem.2020.101385

10. Weiner A, Serwint JR. Diabetes Insipidus. Pediatr Rev. 2020;41(1):41-43. PMID: 32005690 DOI: 10.1542/pir.2018-0337

11. Behl T, Kaur I, Kotwani A. Mechanisms of prolonged lithium therapy-induced nephrogenic diabetes insipidus. Eur J Pharmacol. 2015;755:27-33. PMID: 25746463 DOI: 10.1016/j.ejphar.2015.02.040

12. Christ-Crain M, Gurnell M. Diabetes insipidus. Presse Med. 2021;50(4):104093. PMID: 34718110 DOI: 10.1016/j.lpm.2021.104093

13. Berton AM, Prencipe N, Bertero L, et al. Early Copeptin Determination Allows Prompt Diagnosis of Post-Neurosurgical Central Diabetes Insipidus. Neuroendocrinology. 2020;110(7-8):631-638. PMID: 31484187 DOI: 10.1159/000503145

14. Varaldo E, Prencipe N, Berton AM, et al. Utility of copeptin in predicting non-pathological postoperative polyuria in patients with pituitary adenomas. Pituitary. 2024;27(4):407-415. PMID: 38847919 DOI: 10.1007/s11102-024-01407-x

15. Jinnouchi T, Takata T, Sakamoto S, et al. Lithium-induced Nephrogenic Diabetes Insipidus with Efficacy of Desmopressin in an Elderly Patient. Intern Med. 2024;63(4):555-558. PMID: 37779064 DOI: 10.2169/internalmedicine.2437-23

16. Mutter CM, Smith T, Menze O, et al. Diabetes Insipidus: Pathogenesis, Diagnosis, and Clinical Management. Cureus. 2021;13(2):e13523. PMID: 33786230 DOI: 10.7759/cureus.13523

17. Atila C, Loughrey PB, Christ-Crain M, Winzeler B, Refardt J. Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Lancet Diabetes Endocrinol. 2022;10(10):700-709. PMID: 36007536 DOI: 10.1016/S2213-8587(22)00219-4

18. Lu HA, Yang B, Verkman AS. Diabetes Insipidus. Adv Exp Med Biol. 2017;969:213-225. PMID: 28258576 DOI: 10.1007/978-94-024-1057-0_14

19. Mutter CM, Smith T, Menze O, et al. Diabetes Insipidus: Pathogenesis, Diagnosis, and Clinical Management. Cureus. 2021;13(2):e13523. PMID: 33786230 DOI: 10.7759/cureus.13523

20. de Groot T, Alsady M, Jaklofsky M, et al. Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus. J Am Soc Nephrol. 2016;27(7):2082-91. PMID: 26574046 DOI: 10.1681/ASN.2015070796

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. It is not a substitute for professional medical advice, diagnosis, or treatment. If you have symptoms of diabetes insipidus or any medical condition, please consult a qualified healthcare professional immediately.